Premium
Pharmacoeconomic Issues in the Treatment of Depression
Author(s) -
Saklad Stephen R.
Publication year - 1995
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1995.tb02908.x
Subject(s) - depression (economics) , antidepressant , medicine , psychiatry , intensive care medicine , purchasing , pharmacoeconomics , business , anxiety , marketing , economics , macroeconomics
The advent of newer, more expensive antidepressant agents in the past decade has focused renewed attention on major depressive disorder. The higher costs associated with purchasing the drugs makes their use appear to increase the cost of treating depression. Pharmacoeconomic methods are means of measuring the related advantages and costs, and provide guidance in drug selection. When such measures have been applied, the initial impression of increased costs for treating depressed persons with these agents is not supported. Pharmacoeconomic studies show that the newer antidepressants have clinically significant advantages that translate into lower total health system costs for treating major depressive disorder.